Hepatitis B virus (HBV) is a serious viral infection that affects the liver, potentially leading to liver cirrhosis and liver cancer. Treatments are available, some of which also work against HIV, but they do not usually cure the infection.

Other topics in this section

Hepatitis B: latest news

Hepatitis B resources

  • Hepatitis B

    Hepatitis B virus (HBV) is an infection that can cause severe liver damage, sometimes resulting in death. Hepatitis B is very common around the world, particularly in Africa, the...

    From: Booklets

    Information level Level 2
  • Hepatitis B treatment

    Treatments are available if your immune system does not naturally clear hepatitis B infection. The aims of hepatitis B treatment include stopping HBV replication, reducing liver inflammation, and...

    From: Booklets

    Information level Level 2
  • Hepatitis vaccinations

    Effective vaccinations are available to protect against hepatitis A and hepatitis B. There is currently no vaccine against hepatitis C. All people living with HIV should receive these...

    From: Booklets

    Information level Level 2
  • HIV & hepatitis

    This booklet gives information for people with HIV who also have hepatitis A, hepatitis B or hepatitis C....

    From: Booklets

    Information level Level 2
  • Hepatitis B and HIV

    Hepatitis B is a blood-borne infection that is transmitted in some of the same ways as HIV.Hepatitis B can be prevented...

    From: Factsheets

    Information level Level 2

Hepatitis B features

Hepatitis B news from aidsmap

More news

Hepatitis B news selected from other sources

  • Vosevi safe, effective in ‘triple-infected’ patients with HCV, HBV, HIV

    The direct-acting antiviral Vosevi demonstrated an average sustained virologic response rate of 87% among patients who were “triple-infected” with hepatitis C genotype 3, hepatitis B and HIV, as presented at the American College of Gastroenterology Annual Meeting.

    15 October 2018 | Healio
  • $20 blood test could help diagnose hepatitis B patients across Africa

    Researchers have developed an accurate diagnostic score that consists of inexpensive blood tests to identify patients who require immediate treatment against the deadly hepatitis B virus -- which can lead to liver damage or cancer.

    02 July 2018 | Science Daily
  • 'Virus-cracking' molecules advance fight against hepatitis B

    Researchers have found that certain molecules -- currently under clinical trial -- are able to 'crack' the protective shell of the hepatitis B virus, suggesting it may be possible to attack the virus after it has already taken hold in the body.

    07 February 2018 | Science Daily
  • Deaths Rates of Liver Cirrhosis Exceed Those of 5 Major Cancers

    A new study presented this week at The Liver Meeting® – held by the American Association for the Study of Liver Diseases – found that liver cirrhosis mortality is greater than that of five major cancers, implying the development of appropriate interventions to treat or prevent liver cirrhosis must be prioritized.

    23 October 2017 | AASLD
  • Viral Hepatitis kills more people than HIV, malaria or tuberculosis

    According to the Global Burden of Disease study released today, deaths caused by viral hepatitis have surpassed all chronic infectious diseases including HIV/AIDS, malaria and tuberculosis.

    18 September 2017 | World Hepatitis Alliance
  • Gilead's hepatitis B therapy to vie with 20 Korean therapies

    Korea has approved 20 products made by Korean companies targeting for No.1 chronic hepatitis B therapy Viread (compound: tenofovir disoproxil fumarate) made by Gilead.

    14 August 2017 | Korea Biomedical Review
  • UK rations hepatitis B vaccine amid global shortage

    Holidaymakers planning to travel abroad from the UK may not be able to get their jab in time, say experts.

    08 August 2017 | BBC Health
  • Hepatitis B added to routine baby injections

    All babies born from Tuesday in England, Wales and Northern Ireland will have an anti-hepatitis B injection added to the other routine vaccinations they are given in their early life. The jab protects against viral infections that cause cirrhosis and liver cancer.

    01 August 2017 | BBC News
  • ECDC estimate: Around 9 million Europeans are affected by chronic hepatitis B or C

    An estimated 4.7 million Europeans are living with chronic hepatitis B and almost 4 million with chronic hepatitis C infection. But large numbers of them are not aware of their infection as they have not yet been diagnosed. On of World Hepatitis Day, ECDC Director Andrea Ammon highlights the need for Europe to scale-up coverage of testing, prevention interventions and linkage to suitable treatment services to achieve the target of eliminating viral hepatitis by 2030.

    27 July 2017 | Eurekalert Inf Dis
  • Liver Cancer is What Killed Jailed Chinese Dissident Lu Xiaobo

    The dissident’s plight has come under a global spotlight amid allegations from his supporters that Liu fell gravely ill because his cancer was not detected or treated while he was in prison. Prison authorities said Liu, who also had a history with the hepatitis B virus (HBV) received monthly check-ups and had “no abnormal conditions” before the liver cancer diagnosis.

    17 July 2017 | Hepmag
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.